Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis

Journal of Investigational Allergology and Clinical Immunology

Volumn 21, Issue 5, 2011, Pages 333-347

  Caballero, T ^a   Baeza, Ml ^b,c   Cabanas R ^a   Campos, A ^d   Cimbollek, S ^e   Gomez Traseira C ^a   Gonzalez Quevedo T ^e   Guilarte, M ^f   Jurado Palomo, J ^g   Larco, J I ^a   Lopez Serrano M C ^a   Lopez Trascasa M ^a,c   Marcos, C ^h   Munoz Caro J M ^a   Pedrosa, M ^a   Prior, N ^a   Rubio, M ^b   Sala Cunill, A ^f  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g Hospital General Nuestra Senora del Prado Talavera de la Reina   (Spain)

^h UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

Author keywords

ACE inhibitors; Angioedema; Bradykinin; C1 inhibitor; Estrogens

Indexed keywords

BLOOD CLOTTING FACTOR 12; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; BRADYKININ[1-8]; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C1S INHIBITOR TYPE 1; COMPLEMENT COMPONENT C1S INHIBITOR TYPE 2; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; BLOOD CLOTTING FACTOR 12 GENE; CLINICAL FEATURE; COMPLEMENT COMPONENT C1S INHIBITOR GENE; COMPLEMENT COMPONENT C1S INHIBITOR TYPE 1 GENE; COMPLEMENT COMPONENT C1S INHIBITOR TYPE 2 GENE; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; CONSENSUS; DISEASE SEVERITY; DNA POLYMORPHISM; ENZYME ACTIVATION; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC RISK; HUMAN; IMMUNOGENETICS; IMMUNOPATHOGENESIS; LABORATORY DIAGNOSIS; LARYNX DISORDER; MISSENSE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PROGENY; PROTEIN DETERMINATION; REVIEW; SKIN DISEASE;

ANGIOEDEMA; BRADYKININ; CORONARY VASOSPASM; DRUG HYPERSENSITIVITY; EMERGENCY MEDICAL SERVICES; EVIDENCE-BASED MEDICINE; EXPERT TESTIMONY; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SPAIN; VASODILATOR AGENTS;

EID: 80051740953     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (159)

1. Caballero T, Baeza ML, Cabañas R, Campos A, Cimbollek S, Gómez-Traseira C, González-Quevedo T, Guilarte M, Jurado-Palomo J, Larco JI, López-Serrano MC, López-Trascasa M, Marcos C, Muñoz-Caro JM, Pedrosa M, Prior N, Rubio M, Sala-Cunill A. Spanish Consensus on the Diagnosis, Management And Treatment of Angioedema Mediated by Bradykinin. Part II. Treatment, Follow-Up, and Special Situations. J Investig Allergol Clin Immunol 2011 (in press)
2. Rosen FS, Austen KF. The "neurotic edema" (hereditary angioedema). N Engl J Med. 1969;280:1356-7
3. Rosen FS, Alper CA, Pensky J, Klemperer MR, Donaldson VH. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest. 1971;50:2143-9
4. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356:213-7
5. Binkley KE, Davis A 3rd. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106:546-50
6. Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol. 2009;124:129-34
7. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, Lopez-Trascasa M. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol. 2005;94:498-503
8. Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensinconverting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol. 2007;98:57-63
9. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 1998;18:171-88
10. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006;26:725-37
11. Regulation (EC) no 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. L18, (22-01-2000, 2000)
12. Carter PE, Duponchel C, Tosi M, Fothergill JE. Complete nucleotide sequence of the gene for human C1 inhibitor with an unusually high density of alu elements. Eur J Biochem. 1991;197:301-8
13. Cooper DN, Krawczak M. Mechanisms of insertional mutagenesis in human genes causing genetic disease. Hum Genet. 1991;87:409-15
14. Blanch A, Roche O, Urrutia I, Gamboa P, Fontan G, Lopez-Trascasa M. First case of homozygous C1 inhibitor deficiency. J Allergy Clin Immunol. 2006;118:1330-5
15. López-Lera A, Favier B, Mena de la Cruz R, Garrido S, Drouet C, López-Trascasa M. A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation. J Allergy Clin Immunol. 2010;126:1307-10.e3
16. Quastel M, Harrison R, Cicardi M, Alper CA, Rosen FS. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest. 1983;71:1041-6
17. Pappalardo E, Zingale LC, Cicardi M. C1 inhibitor gene expression in patients with hereditary angioedema: quantitative evaluation by means of real-time RT-PCR. J Allergy Clin Immunol. 2004 Sep;114(3):638-44
18. Tosi M. Molecular genetics of C1 inhibitor. Immunobiology. 1998;199:358-65
19. Blanch A, Roche O, López-Granados E, Fontan G, López-Trascasa M. Detection of C1 inhibitor (SERPING1/C1NH) mutations in exon 8 in patients with hereditary angioedema: evidence for 10 novel mutations. Hum Mutat. 2002;20:405-6
20. Roche O, Blanch A, Duponchel C, Fontan G, Tosi M, López-Trascasa M. Hereditary angioedema: The mutation spectrum of SERPING1/C1NH in a large Spanish cohort. Hum Mutat. 2005;26:135-44
21. Bowen B, Hawk JJ, Sibunka S, Hovick S, Weiler JM. A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations. Clin Immunol. 2001;98:157-63
22. Kalmar L, Bors A, Farkas H, Vas S, Fandl B, Varga L, Füst G, Tordai A. Mutation screening of the C1 inhibitor gene among Hungarian patients with hereditary angioedema. Hum Mutat. 2003;22:498
23. Kalmar L, Hegedus T, Farkas H, Nagy M, Tordai A. HAEdb: A novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum Mutat. 2005;25:1-5
24. Pappalardo E, Caccia S, Suffritti C, Tordai A, Zingale LC, Cicardi M. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol. 2008;45:3536-44
25. Pappalardo E, Cicardi M, Duponchel C, Carugati A, Choquet S, Agostoni A, Tosi M. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol. 2000;106:1147-54
26. Stoppa-Lyonnet D, Tosi M, Laurent J, Sobel A, Lagrue G, Meo T. Altered C1 inhibitor genes in type I hereditary angioedema. N Engl J Med. 1987;317:1-6
27. Stoppa-Lyonnet D, Carter PE, Meo T, Tosi M. Clusters of intragenic alu repeats predispose the human C1 inhibitor locus to deleterious rearrangements. Proc Natl Acad Sci U S A. 1990;87:1551-5
28. Stoppa-Lyonnet D, Duponchel C, Meo T, Laurent J, Carter PE, Arala-Chaves M, Cohen JHM, Dewald G, Goetz J, Hauptmann G, Lagrue G, Lesavre P, Lopez-Trascasa M, Misiano G, Moraine C, Sobel A, Späth PJ, Tosi M. Recombinational biases in the rearranged C1-inhibitor genes of hereditary angioedema patients. Am J Hum Genet. 1991;49:1055-62
29. Carugati A, Pappalardo E, Zingale LC, Cicardi M. C1-inhibitor deficiency and angioedema. Mol Immunol. 2001;38:161-73
30. Donaldson VH, Bissler JJ. C1- inhibitors and their genes: an update. J Lab Clin Med. 1992;119:330-3
31. Dewald G, Bork K. Missense mutations in the coagulation factor XII (hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343:1286-9
32. Cichon S, Martín L, Hennies HC, Muller F, Van Driessche K, Karpushova A, Stevens W, Colombo R, Renné T, Drouet C, Bork K, Nöthen MM. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III Am J Hum Genet. 2006;79:1098-104
33. Bouillet L, Ponard D, Rousset H, Cichon S, Drouet C. A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol. 2007;156:1063-5
34. Bell CG, Kwan E, Nolan RC, Baumgart KW. First molecular confirmation of an Australian case of type III hereditary angioedema. Pathology. 2008;40:82-3
35. Prieto A, Tornero P, Rubio M, Fernández-Cruz E, Rodríguez- Sainz C. Missense mutation Thr309Lys in the coagulation factor XII gene in a Spanish family with hereditary angioedema type III Allergy. 2009;64:284-6
36. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-42
37. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-7
38. Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol. 1999;104:1321-2
39. Sabroe RA, Black AK. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol. 1997;136:153-8
40. Cugno M, Cicardi M, Bottasso B, Coppola R, Paonessa R, Mannucci PM, Agostoni A. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood. 1997;89:3213-8
41. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3:311-7
42. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347:621-2
43. Davis AE 3rd. The pathogenesis of hereditary angioedema. Transfus Apher Sci. 2003;29:195-203
44. Davis AE 3rd. The pathophysiology of hereditary angioedema. Clin Immunol. 2005;114:3-9
45. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1- inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 2009;15:69-78
46. Kaplan AP, Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol. 2010;47:2161-9
47. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1-80
48. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005;57:27-77
49. McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P, Fujisaki J, Aldrich RW, Jarnagin K. Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci U S A. 1991;88:7724-8
50. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The kallikrein-kinin system: Current and future pharmacological targets. J Pharmacol Sci. 2005;99:6-38
51. Erdos EG, Sloane EM. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem Pharmacol. 1962;11:585-92
52. Blais C Jr, Rouleau JL, Brown NJ, Lepage Y, Spence D, Munoz C, Friborg J, Geadah D, Gervais N, Adam A. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology. 1999;43:293-302
53. Cyr M, Lepage Y, Blais C, Jr, Gervais N, Cugno M, Rouleau JL, Adam A. Bradykinin and des-arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol. 2001 Jul;281(1):H275-83
54. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE 3rd. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002 Apr;109(8):1057-63
55. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (icatibant). J Allergy Clin Immunol. 2007;119:1497-503
56. Bossi F, Fischetti F, Regoli D, Durigutto P, Frossi B, Gobeil F Jr, Ghebrehiwet B, Peerschke EI, Cicardi M, Tedesco F. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol. 2009;124:1303,10.e4
57. Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Schneck KA, Ransom RW, Strader CD, Linemeyer DL, Hess JF. Expression cloning of a human B1 bradykinin receptor. J Biol Chem. 1994;269:21583-6
58. Marceau F, Bachvarov DR. Kinin receptors. Clin Rev Allergy Immunol. 1998;16:385-401
59. Marceau F, Sabourin T, Houle S, Fortin JP, Petitclerc E, Molinaro G, Adam A. Kinin receptors: functional aspects. Int Immunopharmacol. 2002;2:1729-39
60. Bouillet L, Longhurst H, Boccon-Gibod I, Bork K, Bucher C, Bygum A, Caballero T, Drouet C, Farkas H, Massot C, Nielsen EW, Ponard D, Cicardi M. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199:484.e1,484.e4
61. Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med. 2003;114:294-8
62. Gordon EM, Ratnoff OD, Saito H, Donaldson VH, Pensky J, Jones PK. Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives. J Lab Clin Med. 1980;96:762-9
63. Citarella F, Misiti S, Felici A, Farsetti A, Pontecorvi A, Fantoni A. Estrogen induction and contact phase activation of human factor XII. Steroids. 1996;61:270-6
64. Gordon EM, Douglas JG, Ratnoff OD, Arafah BM. The infl uence of estrogen and prolactin on Hageman factor (factor XII) titer in ovariectomized and hypophysectomized rats. Blood. 1985;66:602-5
65. Chen LM, Chung P, Chao S, Chao L, Chao J. Differential regulation of kininogen gene expression by estrogen and progesterone in vivo. Biochim Biophys Acta. 1992;1131:145-51
66. Hoem NO, Johannesen S, Hauge G, Rud AC, Sandem S, Briseid K. Contact activation factors in plasma from women using oral contraceptives--increased levels of factor XII, kinin-free high molecular weight kininogen and acetone-activated kallikrein. Thromb Res. 1991;64:427-34
67. Wessler S. Estrogen-associated thromboembolism. Ann Epidemiol. 1992;2:439-43
68. Campbell SJ, Mackie IJ, Robinson GE, Machin SJ. Contact factor mediated fibrinolysis is increased by the combined oral contraceptive pill. Br J Obstet Gynaecol. 1993;100:79-84
69. Farsetti A, Misiti S, Citarella F, Felici A, Andreoli M, Fantoni A, Sacchi A, Pontecorvi A. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology. 1995;136:5076-83
70. Nogawa N, Sumino H, Ichikawa S, Kumakura H, Takayama Y, Nakamura T, Kanda T, Mizunuma H, Kurabayashi M. Effect of long-term hormone replacement therapy on angiotensinconverting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women. Menopause. 2001;8:210-5
71. Gallagher PE, Li P, Lenhart JR, Chappell MC, Brosnihan KB. Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension. 1999;33:323-8
72. Sumino H, Ichikawa S, Ohyama Y, Nakamura T, Kanda T, Sakamoto H, Sakamaki T, Mizunuma H, Kurabayashi M. Effects of hormone replacement therapy on serum angiotensinconverting enzyme activity and plasma bradykinin in postmenopausal women according to angiotensin-converting enzyme-genotype. Hypertens Res. 2003;26:53-8
73. Madeddu P, Emanueli C, Song Q, Varoni MV, Demontis MP, Anania V, Glorioso N, Chao J. Regulation of bradykinin B2-receptor expression by oestrogen. Br J Pharmacol. 1997;121:1763-9
74. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, Bucher C, Castaldo AJ, Cicardi M, Davis AE, De Carolis C, Drouet C, Duponchel C, Farkas H, Fáy K, Fekete B, Fischer B, Fontana L, Füst G, Giacomelli R, Gröner A, Hack CE, Harmat G, Jakenfelds J, Juers M, Kalmár L, Kaposi PN, Karádi I, Kitzinger A, Kollár T, Kreuz W, Lakatos P, Longhurst HJ, Lopez-Trascasa M, Martinez-Saguer I, Monnier N, Nagy I, Németh E, Nielsen EW, Nuijens JH, O'grady C, Pappalardo E, Penna V, Perricone C, Perricone R, Rauch U, Roche O, Rusicke E, Späth PJ, Szendei G, Takács E, Tordai A, Truedsson L, Varga L, Visy B, Williams K, Zanichelli A, Zingale L. Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3 Suppl):S51-131
75. Schousboe I, Rasmussen MS, Lintner R. Dextran sulphate inhibits phospholipid and sulphatide mediated autoactivation of factor XII. Blood Coagul Fibrinolysis. 1994;5:503-9
76. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O'Donnell E, Salvesen GS, Travis J, Whisstock JC. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem. 2001;276:33293-6
77. Johnson AM, Alper CA, Rosen FS, Craig JM. C1 inhibitor: Evidence for decreased hepatic synthesis in hereditary angioneurotic edema. Science. 1971;173:553-4
78. Strang CJ, Cholin S, Spragg J, Davis AE 3rd, Schneeberger EE, Donaldson VH, Rosen FS. Angioedema induced by a peptide derived from complement component C2. J Exp Med. 1988 Nov 1;168:1685-98
79. Donaldson VH, Rosen FS. Action of complement in hereditary angioneurotic edema: the role of C'1-esterase. J Clin Invest. 1964;43:2204-13
80. Cugno M, Cicardi M, Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: A rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol. 1994;93:870-6
81. Cugno M, Hack CE, de Boer JP, Eerenberg AJ, Agostoni A, Cicardi M. Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med. 1993;121:38-43
82. Kleniewski J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med. 1992;120:129-39
83. Zingale LC, Castelli R, Zanichelli A, Cicardi M. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am. 2006;26:669-90
84. Schreiber AD, Zweiman B, Atkins P, Goldwein F, Pietra G, Atkinson B, Abdou NI. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood. 1976;48:567-80
85. Hauptmann G, Petitjean F, Lang JM, Oberling F. Acquired C1 inhibitor deficiency in a case of lymphosarcoma of the spleen. Reversal of complement abnormalities after splenectomy. Clin Exp Immunol. 1979;37:523-31
86. Geha RS, Quinti I, Austen KF, Cicardi M, Sheffer A, Rosen FS. Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N Engl J Med. 1985;312:534-40
87. Melamed J, Alper CA, Cicardi M, Rosen FS. The metabolism of C1 inhibitor and C1q in patients with acquired C1-inhibitor deficiency. J Allergy Clin Immunol. 1986;77:322-6
88. Jackson J, Sim RB, Whaley K, Feighery C. Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema. J Clin Invest. 1989;83:698-707
89. Bouillet-Claveyrolas L, Ponard D, Drouet C, Massot C. Clinical and biological distinctions between type I and type II acquired angioedema. Am J Med. 2003;115:420-1
90. Ponce IM, Caballero T, Reche M, Piteiro AB, López-Serrano MC, Fontan G, López-Trascasa M. Polyclonal autoantibodies against C1 inhibitor in a case of acquired angioedema. Ann Allergy Asthma Immunol. 2002;88:632-7
91. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992;71:206-15
92. Vitrat-Hincky V, Gompel A, Dumestre-Perard C, Boccon-Gibod I, Drouet C, Cesbron JY, Lunardi J, Massot C, Bouillet L. Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy. 2010;65:1331-6
93. Bork K. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin Immunol. 2010;6:15
94. Bouillet L, Ponard D, Drouet C, Massot C. [Non-histaminic angiodema management: Diagnostic and therapeutic interest of tranexamic acid]. Rev Med Interne. 2004;25:924-6
95. Bouillet L, Boccon-Gibod I, Ponard D, Drouet C, Cesbron JY, Dumestre-Perard C, Monnier N, Lunardi J, Massot C, Gompel A. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol. 2009;103:448
96. Bork K, Kleist R, Hardt J, Witzke G. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Blood Coagul Fibrinolysis. 2009;20:325-32
97. Klein-Hitpass L, Tsai SY, Greene GL, Clark JH, Tsai MJ, O'Malley BW. Specific binding of estrogen receptor to the estrogen response element. Mol Cell Biol. 1989;9:43-9
98. Duan QL, Binkley K, Rouleau GA. Genetic analysis of factor XII and bradykinin catabolic enzymes in a family with estrogendependent inherited angioedema. J Allergy Clin Immunol. 2009;123:906-10
99. Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACEinhibitor- associated angioedema. Hypertension. 2002;39:460-4
100. Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, Adam A, Brown NJ. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008;51:141-7
101. Orr KK, Myers JR. Intermittent visceral edema induced by long-term enalapril administration. Ann Pharmacother. 2004;38:825-7
102. Molinaro G, Cugno M, Pérez M, Lepage Y, Gervais N, Agostoni A, Adam A. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of desarginine(9)-bradykinin. J Pharmacol Exp Ther. 2002;303:232-7
103. Kim KS, Kumar S, Simmons WH, Brown NJ. Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans. J Pharmacol Exp Ther. 2000;292:295-8
104. Duan QL, Nikpoor B, Dube MP, Molinaro G, Meijer IA, Dion P, Rochefort D, Saint-Onge J, Flury L, Brown NJ, Gainer JV, Rouleau JL, Agostoni A, Cugno M, Simon P, Clavel P, Potier J, Wehbe B, Benarbia S, Marc-Aurele J, Chanard J, Foroud T, Adam A, Rouleau GA. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet. 2005;77:617-26
105. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990 Oct;86(4):1343-6
106. Murphey LJ, Gainer JV, Vaughan DE, Brown NJ. Angiotensinconverting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation. 2000;102:829-32
107. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976;84:580-93
108. Carreer FM. The C1 inhibitor deficiency. A review. Eur J Clin Chem Clin Biochem. 1992;30:793-807
109. Farkas H, Harmat G, Fay A, Fekete B, Karadi I, Visy B, Varga L. Erythema marginatum preceding an acute oedematous attack of hereditary angioneurotic oedema. Acta Derm Venereol. 2001;81:376-7
110. Farkas H, Fust G, Fekete B, Karadi I, Varga L. Eradication of Helicobacter pylori and improvement of hereditary angioneurotic oedema. Lancet. 2001;358:1695-6
111. Visy B, Fust G, Bygum A, Bork K, Longhurst H, Bucher C, Bouillet L, Cicardi M, Farkas H. Helicobacter pylori infection as a triggering factor of attacks in patients with hereditary angioedema. Helicobacter. 2007;12:251-7
112. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119:267-74
113. Winnewisser J, Rossi M, Spath P, Burgi H. Type I hereditary angio-oedema. variability of clinical presentation and course within two large kindreds. J Intern Med. 1997;241:39-46
114. Talavera A, Larraona JL, Ramos JL, López T, Maraver A, Arias J, Barrios A. Hereditary angioedema: An infrequent cause of abdominal pain with ascites. Am J Gastroenterol. 1995;90:471-4
115. Cicardi M, Bergamaschini L, Cugno M, Beretta A, Zingale LC, Colombo M, Agostoni A. Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology. 1998;199:366-76
116. Frank MM. C1 esterase inhibitor: clinical clues to the pathophysiology of angioedema. J Allergy Clin Immunol. 1986;78:848-50
117. Cohen N, Sharon A, Golik A, Zaidenstein R, Modai D. Hereditary angioneurotic edema with severe hypovolemic shock. J Clin Gastroenterol. 1993;16:237-9
118. Bork K. Hypovolemic shock caused by ascites in hereditary angioedema. Med Klin (Munich). 1998;93:554
119. Caballero T, López-Serrano MC. Angioedema por déficit de C1-inhibidor. Rev Esp Alergol Immunol Clin. 2000;15:148-54
120. Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163:1229-35
121. Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc. 2000;75:349-54
122. Van Dellen RC, Myers RP. Bladder involvement in hereditary angioedema. Mayo Clin Proc. 1980;55:277-8
123. Nielsen EW, Gran JT, Straume B, Mellbye OJ, Johansen HT, Mollnes TE. Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. J Intern Med. 1996;239:119-30
124. Farkas H, Harmat G, Fust G, Varga L, Visy B. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol. 2002 Jun;13:153-61
125. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, Fay AC, Longhurst HJ, Morrison L, Price A, Price M, Watters D. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139:379-94
126. Donaldson VH, Rosen FS. Hereditary angioneurotic edema: a clinical survey. Pediatrics. 1966;37:1017-27
127. Gwynn CM. Therapy in hereditary angioneurotic oedema. Arch Dis Child. 1974;49:636-40
128. Bowen T, Cicardi M, Farkas H, Bork K, Kreuz W, Zingale L, Varga L, Martinez-Saguer I, Aygören-Pürsün E, Binkley K, Zuraw B, Davis A 3rd, Hebert J, Ritchie B, Burnham J, Castaldo A, Menendez A, Nagy I, Harmat G, Bucher C, Lacuesta G, Issekutz A, Warrington R, Yang W, Dean J, Kanani A, Stark D, McCusker C, Wagner E, Rivard GE, Leith E, Tsai E, MacSween M, Lyanga J, Serushago B, Leznoff A, Waserman S, de Serres J. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol. 2004;114:629-37
129. Binkley KE, Davis AE 3rd. Estrogen-dependent inherited angioedema. Transfus Apher Sci. 2003;29:215-9
130. Cicardi M, Zingale L. How do we treat patients with hereditary angioedema. Transfus Apher Sci. 2003;29:221-7
131. Bowen T, Cicardi M, Bork K, Zuraw B, Frank M, Ritchie B, Farkas H, Varga L, Zingale LC, Binkley K, Wagner E, Adomaitis P, Brosz K, Burnham J, Warrington R, Kalicinsky C, Mace S, McCusker C, Schellenberg R, Celeste L, Hebert J, Valentine K, Poon MC, Serushago B, Neurath D, Yang W, Lacuesta G, Issekutz A, Hamed A, Kamra P, Dean J, Kanani A, Stark D, Rivard GE, Leith E, Tsai E, Waserman S, Keith PK, Page D, Marchesin S, Longhurst HJ, Kreuz W, Rusicke E, Martinez-Saguer I, Aygören- Pürsün E, Harmat G, Füst G, Li H, Bouillet L, Caballero T, Moldovan D, Späth PJ, Smith-Foltz S, Nagy I, Nielsen EW, Bucher C, Nordenfelt P, Xiang ZY. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol. 2008;100(1 Suppl 2):S30-40
132. Bouillet L, Ponard D, Drouet C, Jullien D, Massot C. Angioedema and oral contraception. Dermatology. 2003;206:106-9
133. Sheffer AL, Austen KF, Rosen FS, Fearon DT. Acquired deficiency of the inhibitor of the first component of complement: report of five additional cases with commentary on the syndrome. J Allergy Clin Immunol. 1985;75:640-6
134. Cicardi M, Bisiani G, Cugno M, Spath P, Agostoni A. Autoimmune C1 inhibitor deficiency: report of eight patients. Am J Med. 1993;95:169-75
135. Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A. Autoantibodies and lymphoproliferative diseases in acquired C1- inhibitor deficiencies. Medicine (Baltimore). 2003;82:274-81
136. Castelli R, Deliliers DL, Zingale LC, Pogliani EM, Cicardi M. Lymphoproliferative disease and acquired C1 inhibitor deficiency. Haematologica. 2007;92:716-8
137. Cugno M, Castelli R, Cicardi M. Angioedema due to acquired C1- inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. Autoimmun Rev. 2008;8:156-9
138. Martin L, Raison-Peyron N, Nothen MM, Cichon S, Drouet C. Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. J Allergy Clin Immunol. 2007;120:975-7
139. Bork K, Gul D, Hardt J, Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med. 2007 Nov;120(11):987-92
140. Giannoccaro PJ, Wallace GJ, Higginson LA, Williams WL. Fatal angioedema associated with enalapril. Can J Cardiol. 1989;5:335-6
141. Jason DR. Fatal angioedema associated with captopril. J Forensic Sci. 1992;37:1418-21
142. Oike Y, Ogata Y, Higashi D, Matsumura T, Numata Y. Fatal angioedema associated with enalapril. Intern Med. 1993;32:308-10
143. Ulmer JL, Garvey MJ. Fatal angioedema associated with lisinopril. Ann Pharmacother. 1992;26:1245-6
144. Schmidt TD, McGrath KM. Angiotensin-converting enzyme inhibitor angioedema of the intestine: a case report and review of the literature. Am J Med Sci. 2002;324:106-8
145. Tarzi MD, Hickey A, Forster T, Mohammadi M, Longhurst HJ. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin Exp Immunol. 2007;149:513-6
146. Karim Y, Griffiths H, Deacock S. Normal complement C4 values do not exclude hereditary angioedema. J Clin Pathol. 2004;57:213-4
147. Zuraw BL, Sugimoto S, Curd JG. The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency. J Allergy Clin Immunol. 1986;78:1115-20
148. Gompels MM, Lock RJ, Morgan JE, Osborne J, Brown A, Virgo PF. A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J Clin Pathol. 2002;55:145-7
149. Massa MC, Connolly SM. An association between C1 esterase inhibitor deficiency and lupus erythematosus: report of two cases and review of the literature. J Am Acad Dermatol. 1982;7:255-64
150. Farkas H, Csepregi A, Nemesanszky E, Par A, Gyeney L, Varga L, Füst G. Acquired angioedema associated with chronic hepatitis C. J Allergy Clin Immunol. 1999;103:711-2
151. Gerencer M, Burek V, Barrett NP, Dorner F. Acquired deficiency of functional C1-esterase inhibitor in HIV type 1-infected patients. AIDS Res Hum Retroviruses. 1997;13:813-4
152. Brickman CM, Tsokos GC, Chused TM, Balow JE, Lawley TJ, Santaella M, Hammer CH, Linton GF, Frank MM. Immunoregulatory disorders associated with hereditary angioedema. II. Serologic and cellular abnormalities. J Allergy Clin Immunol. 1986;77:758-67
153. Wagenaar-Bos IG, Drouet C, Aygoren-Pursun E, Bork K, Bucher C, Bygum A, Farkas H, Fust G, Gregorek H, Hack CE, Hickey A, Joller-Jemelka HI, Kapusta M, Kreuz W, Longhurst H, Lopez-Trascasa M, Madalinski K, Naskalski J, Nieuwenhuys E, Ponard D, Truedsson L, Varga L, Nielsen EW, Wagner E, Zingale L, Cicardi M, van Ham SM. Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. J Immunol Methods. 2008 Sep 30;338(1-2):14-20
154. Weiler CR, van Dellen RG. Genetic test indications and interpretations in patients with hereditary angioedema. Mayo Clin Proc. 2006;81:958-72
155. Zuraw BL. Diagnosis and management of hereditary angioedema: an American approach. Transfus Apher Sci. 2003;29:239-45
156. Nielsen EW, Johansen HT, Holt J, Mollnes TE. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res. 1994;35:184-7
157. Branco-Ferreira M, Pedro E, Barbosa MA, Carlos AG. Ascites in hereditary angioedema. Allergy. 1998;53:543-5
158. Laurent J, Toulet R, Lagrue G. Ultrasonography in the diagnosis of hereditary angioneurotic oedema. Lancet. 1988;1:761
159. Sadeghi N, Van Daele D, Hainaux B, Engelholm L, Michel O. Hereditary angio-edema involving the gastrointestinal tract: CT findings. Eur Radiol. 2001;11:99-101.